PYC Therapeutics Limited (PYC.AX)

ASX - ASX Delayed price. Currency in AUD

Add to watchlist

0.0920

-0.0010

(-1.08%)

At close: 04:10PM AEST

Loading interactive chart…

Simply Wall St.
Here's Why We're Not Too Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St.
Owning 57% in PYC Therapeutics Limited (ASX:PYC) means that insiders are heavily invested in the company's future
Key Insights Insiders appear to have a vested interest in PYC Therapeutics' growth, as seen by their sizeable ownership...
PR Newswire
PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE
PYC Therapeutics today announces the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication[8].